세계의 후천성 혈우병 치료 시장 보고서(2025년)

Acquired Hemophilia Treatment Global Market Report 2025

US $ 4,490 ￦ 6,426,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,288,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,150,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

후천성 혈우병 치료 시장 규모는 향후 몇 년 동안 안정적인 성장을 보일 것으로 예상되며, 2029년에는 4.7%의 CAGR로 155억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 세계 인구 증가, 헬스케어 투자 증가, 맞춤형 의료 트렌드, 국제 공동 연구, 헬스케어 인식 증가, 희귀질환 치료제에 대한 규제 당국의 지원 등에 기인하는 것으로 분석됩니다. 예측 기간의 주요 동향으로는 모니터링 및 진단 기술 강화, 환자 지원 프로그램 연계, 유전자 치료 접근법 연구, 면역관용 도입의 이용 확대, 원격진료를 위한 원격의료 등을 들 수 있습니다.

후천성 혈우병 치료 시장의 성장이 기대되는 이유는 진행 중인 임상시험의 증가에 기인합니다. 후천성 혈우병의 새로운 치료법의 안전성과 유효성을 평가하는 데 있어 인간을 대상으로 한 조사 연구를 포함한 임상시험은 중요한 역할을 합니다. ClinicalTrials.gov에 따르면, 2023년 10월 현재 전 세계적으로 등록된 임상시험 수는 2022년 437,523건에서 미국 50개 주와 221개국에서 468, 457건으로 증가했습니다. 457건으로 증가했습니다. 미국에서만 143,613건(전체의 31%), 미국 외 지역에서는 251,159건(전체의 54%)이 등록되어 있습니다. 따라서 진행 중인 임상시험 수의 증가는 후천성 혈우병 치료 시장의 중요한 촉진요인이 되고 있습니다.

헬스케어 지출의 증가는 향후 후천성 혈우병 치료 시장의 성장을 촉진할 것으로 예상됩니다. 헬스케어 지출은 특정 기간 동안 헬스케어 상품 및 서비스에 지출된 총 금액을 의미하며, 일반적으로 금액으로 표시됩니다. 이 지출은 후천성 혈우병 치료에 필수적이며, 고급 치료, 의료 개입, 종합적인 치료에 대한 접근을 가능하게 하고 궁극적으로 환자의 결과와 이 희귀 출혈성 질환의 전반적인 관리에 영향을 미치기 때문에 필수적입니다. 예를 들어, 2022년 3월 미국 연방정부 기관인 메디케어 및 메디케이드 서비스 센터는 2021-2030년 국민의료비(NHE) 보고서를 발표하면서 2021-2030년 사이 국민의료비가 연평균 5.1%씩 증가하여 약 6조 8,000억 달러에 달할 것으로 예측했습니다. 되고 있는 것으로 나타났습니다. 또한, 메디케어 지출은 연평균 7.2%, 메디케이드 지출은 같은 기간 동안 5.6% 증가할 것으로 예상됩니다. 이처럼 의료비 지출의 증가는 후천성 혈우병 치료 시장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 후천성 혈우병 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 후천성 혈우병 치료 시장 : 성장률 분석
• 세계의 후천성 혈우병 치료 시장 실적 : 규모와 성장, 2019-2024
• 세계의 후천성 혈우병 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 후천성 혈우병 치료 전체 시장(TAM)

제6장 시장 세분화

• 세계의 후천성 혈우병 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 주문형
• 예방
• 세계의 후천성 혈우병 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 혈우병 A
• 혈우병 B
• 혈우병 C
• 기타 유형
• 세계의 후천성 혈우병 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 클리닉
• 기타 최종사용자
• 세계의 후천성 혈우병 치료 시장, 주문형 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 응고인자 보충 요법
• 데스모프레신
• 기타 주문형 치료
• 세계의 후천성 혈우병 치료 시장, 예방법 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 응고인자 보충 요법
• 유전자 치료
• 기타 예방 치료

제7장 지역별·국가별 분석

• 세계의 후천성 혈우병 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 후천성 혈우병 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 후천성 혈우병 치료 시장 : 경쟁 구도
• 후천성 혈우병 치료 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Sanofi SA
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Novo Nordisk A/S
• Baxter Healthcare Corporation
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Biogen Inc.
• CSL Limited
• Grifols SA
• Genentech Inc.
• Octapharma AG
• Ferring Pharmaceuticals BV
• Shire plc

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 후천성 혈우병 치료 시장 2029 : 새로운 기회를 제공하는 국가
• 후천성 혈우병 치료 시장 2029 : 새로운 기회를 제공하는 부문
• 후천성 혈우병 치료 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

The treatment of acquired hemophilia refers to therapeutic approaches utilized to manage and address this non-hereditary bleeding disorder. It arises from a mutation or alteration in one of the genes responsible for producing clotting factor proteins crucial for blood clot formation. The treatment involves various strategies, including controlling bleeding episodes and eliminating inhibitors that target clotting factors.

The primary treatments for acquired hemophilia include on-demand and prophylaxis. On-demand treatment involves administering clotting factor replacement therapy only in response to clinically significant bleeding. Hospitals, clinics, and other end users prescribe this treatment for hemophilia A, hemophilia B, hemophilia C, and other related conditions.

The acquired hemophilia treatment market research report is one of a series of new reports from The Business Research Company that provides acquired hemophilia treatment market statistics, including acquired hemophilia treatment industry global market size, regional shares, competitors with an acquired hemophilia treatment market share, detailed acquired hemophilia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acquired hemophilia treatment industry. This acquired hemophilia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acquired hemophilia treatment market size has grown strongly in recent years. It will grow from $12.2 billion in 2024 to $12.96 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing ageing population, improved diagnostics and awareness, expanding patient pool, collaborative research initiatives, regulatory support and approvals.

The acquired hemophilia treatment market size is expected to see steady growth in the next few years. It will grow to $15.56 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to growing global population, rising healthcare investments, personalized medicine trends, international collaborations in research, increasing healthcare awareness, regulatory support for orphan drugs. Major trends in the forecast period include enhanced monitoring and diagnostic technologies, collaboration for patient support programs, research on gene therapy approaches, increased utilization of immune tolerance induction, telemedicine for remote consultations.

The anticipated growth in the acquired hemophilia treatment market is expected to be driven by an increasing number of ongoing clinical trials. Clinical trials, which involve research studies with human participants, play a crucial role in evaluating the safety and effectiveness of new medical treatments for acquired hemophilia. These trials contribute to advancing research, enhancing patient outcomes, and establishing effective therapeutic interventions. As of October 2023, according to ClinicalTrials.gov, the number of registered studies globally increased from 437,523 in 2022 to 468,457 across all 50 states in the United States and 221 countries. The U.S. alone accounted for 143,613 studies (31% of the total), while non-U.S. locations registered 251,159 studies (54% of the total). Hence, the growing number of ongoing clinical trials is a significant driver for the acquired hemophilia treatment market.

The rising healthcare expenditure is anticipated to drive the growth of the acquired hemophilia treatment market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services over a specific period, typically expressed in monetary terms. This expenditure is vital for acquired hemophilia treatment as it enables access to advanced therapies, medical interventions, and comprehensive care, ultimately influencing patient outcomes and the overall management of this rare bleeding disorder. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a federal agency in the U.S., published the 2021-2030 National Health Expenditure (NHE) report, indicating that national health spending is projected to grow at an average rate of 5.1% annually between 2021 and 2030, reaching nearly $6.8 trillion. Furthermore, Medicare spending is expected to rise at an annual rate of 7.2%, while Medicaid spending will increase at a rate of 5.6% during the same period. Thus, the growth in healthcare expenditure is propelling the acquired hemophilia treatment market forward.

Major companies in the acquired hemophilia treatment market are actively focused on obtaining approvals for drugs with additional measures to strengthen their market position. Drug approvals that include routine prophylaxis are increasing, addressing the need for more effective and safer treatment options. For instance, in June 2022, Chugai Pharmaceutical received extended approval from Japan's Ministry of Health, Labor and Welfare to expand the use of Hemlibra (emicizumab) for routine prophylaxis in acquired hemophilia A patients, aiming to reduce or minimize the occurrence of bleeds. This bispecific antibody simultaneously targets factor IX and factor X binding sites, enhancing the control of bleeding in patients.

In June 2023, Baudax Bio. completed the acquisition of TeraImmune Inc., an advanced research company based in the U.S., for an undisclosed amount. This strategic move aimed to combine TeraImmune's scientific expertise with Baudax Bio.'s proficiency in executing clinical development programs. The acquisition incorporated TeraImmune's TI-168 asset, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to neutralize clotting factor VIII (FVIII) inhibitors in Hemophilia A patients. TeraImmune Inc. contributed valuable advancements in the field of treatments for hemophilia.

Major companies operating in the acquired hemophilia treatment market report are Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc., CSL Limited, Grifols SA, Genentech Inc., Octapharma AG, Ferring Pharmaceuticals BV, Shire PLC, BioMarin Pharmaceutical Inc., Sobi Inc., Kedrion Biopharma Inc., Chugai Pharmaceutical Co. Ltd., Spark Therapeutics Inc., Medexus Pharmaceuticals Inc., UniQure NV, Catalyst Biosciences Inc., Hema Biologics LLC, BioXcel Corporation

North America was the largest region in the acquired hemophilia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acquired hemophilia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acquired hemophilia treatment market consists of revenues earned by entities by providing services such as eradication of inhibitors, individualized therapeutic approach, multidisciplinary approach, and prevention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired hemophilia treatment market also includes sales of immunosuppressive agents including cyclosporine A, and azathioprine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acquired Hemophilia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acquired hemophilia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acquired hemophilia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired hemophilia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: On-Demand; Prophylaxis
• 2) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
• 3) By End User: Hospitals; Clinic; Other End Users
• Subsegments:
• 1) By On-Demand: Clotting Factor Replacement Therapy; Desmopressin; Other On-Demand Treatments
• 2) By Prophylaxis: Clotting Factor Replacement Therapy; Gene Therapy; Other Prophylaxis Treatments
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Bayer AG; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acquired Hemophilia Treatment Market Characteristics

3. Acquired Hemophilia Treatment Market Trends And Strategies

4. Acquired Hemophilia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acquired Hemophilia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acquired Hemophilia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acquired Hemophilia Treatment Market Growth Rate Analysis
• 5.4. Global Acquired Hemophilia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acquired Hemophilia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acquired Hemophilia Treatment Total Addressable Market (TAM)

6. Acquired Hemophilia Treatment Market Segmentation

• 6.1. Global Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• On-Demand
• Prophylaxis
• 6.2. Global Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Other Types
• 6.3. Global Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinic
• Other End Users
• 6.4. Global Acquired Hemophilia Treatment Market, Sub-Segmentation Of On-Demand, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clotting Factor Replacement Therapy
• Desmopressin
• Other On-Demand Treatments
• 6.5. Global Acquired Hemophilia Treatment Market, Sub-Segmentation Of Prophylaxis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clotting Factor Replacement Therapy
• Gene Therapy
• Other Prophylaxis Treatments

7. Acquired Hemophilia Treatment Market Regional And Country Analysis

• 7.1. Global Acquired Hemophilia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acquired Hemophilia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acquired Hemophilia Treatment Market

• 8.1. Asia-Pacific Acquired Hemophilia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acquired Hemophilia Treatment Market

• 9.1. China Acquired Hemophilia Treatment Market Overview
• 9.2. China Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acquired Hemophilia Treatment Market

• 10.1. India Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acquired Hemophilia Treatment Market

• 11.1. Japan Acquired Hemophilia Treatment Market Overview
• 11.2. Japan Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acquired Hemophilia Treatment Market

• 12.1. Australia Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acquired Hemophilia Treatment Market

• 13.1. Indonesia Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acquired Hemophilia Treatment Market

• 14.1. South Korea Acquired Hemophilia Treatment Market Overview
• 14.2. South Korea Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acquired Hemophilia Treatment Market

• 15.1. Western Europe Acquired Hemophilia Treatment Market Overview
• 15.2. Western Europe Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acquired Hemophilia Treatment Market

• 16.1. UK Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acquired Hemophilia Treatment Market

• 17.1. Germany Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acquired Hemophilia Treatment Market

• 18.1. France Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acquired Hemophilia Treatment Market

• 19.1. Italy Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acquired Hemophilia Treatment Market

• 20.1. Spain Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acquired Hemophilia Treatment Market

• 21.1. Eastern Europe Acquired Hemophilia Treatment Market Overview
• 21.2. Eastern Europe Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acquired Hemophilia Treatment Market

• 22.1. Russia Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acquired Hemophilia Treatment Market

• 23.1. North America Acquired Hemophilia Treatment Market Overview
• 23.2. North America Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acquired Hemophilia Treatment Market

• 24.1. USA Acquired Hemophilia Treatment Market Overview
• 24.2. USA Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acquired Hemophilia Treatment Market

• 25.1. Canada Acquired Hemophilia Treatment Market Overview
• 25.2. Canada Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acquired Hemophilia Treatment Market

• 26.1. South America Acquired Hemophilia Treatment Market Overview
• 26.2. South America Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acquired Hemophilia Treatment Market

• 27.1. Brazil Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acquired Hemophilia Treatment Market

• 28.1. Middle East Acquired Hemophilia Treatment Market Overview
• 28.2. Middle East Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acquired Hemophilia Treatment Market

• 29.1. Africa Acquired Hemophilia Treatment Market Overview
• 29.2. Africa Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acquired Hemophilia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Acquired Hemophilia Treatment Market Competitive Landscape
• 30.2. Acquired Hemophilia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Acquired Hemophilia Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Amgen Inc.
• 31.5. Novo Nordisk A/S
• 31.6. Baxter Healthcare Corporation
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Mylan NV
• 31.9. Biogen Inc.
• 31.10. CSL Limited
• 31.11. Grifols SA
• 31.12. Genentech Inc.
• 31.13. Octapharma AG
• 31.14. Ferring Pharmaceuticals BV
• 31.15. Shire plc

32. Global Acquired Hemophilia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acquired Hemophilia Treatment Market

34. Recent Developments In The Acquired Hemophilia Treatment Market

35. Acquired Hemophilia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Acquired Hemophilia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acquired Hemophilia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acquired Hemophilia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료